Georgia Clinical Trials Report — May 2026

For Georgians considering participation in clinical research, May 2026 presents a crucial opportunity, especially for those looking to join studies that are nearing their enrollment deadlines. Across the state, 148 clinical trials are slated to close within the next 90 days. This urgency extends to healthy volunteers, with 16 of these rapidly closing studies actively seeking participants without specific health conditions. Individuals interested in contributing to medical advancements should explore these options promptly before they are no longer available.

Patients managing certain health conditions also face impending deadlines to join research. Trials focused on sickle cell disease, heart failure, and HIV infections are among those with limited time remaining for enrollment. Conditions with trials closing soon include:

• Sickle cell disease
• Heart failure
• HIV infections
• Advanced breast cancer
• Stage IV lung cancer AJCC V8
• Gastric cancer
• Interstitial cystitis
• Autism spectrum disorder
• Breast cancer
• Bladder pain syndrome

Major Research Initiatives Launch in Georgia

This month brings several high-profile new trials to Georgia, including significant Phase 3 studies from major pharmaceutical companies and leading academic institutions. These trials offer participants the chance to engage with cutting-edge treatments and diagnostic tools, addressing a range of health challenges from metabolic disorders to infectious diseases.

• Novo Nordisk A/S is sponsoring NCT07567001, a Phase 3 study titled "A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity." This substantial trial aims to enroll 5,610 participants globally, evaluating the safety and effect of NNC0487-0111 in individuals with Heart Failure with preserved Ejection Fraction (HFpEF) or Heart Failure with mildly reduced Ejection Fraction (HFmrEF) and excess body weight.
• Another significant Phase 3 study from Novo Nordisk A/S is NCT07564414, "A Research Study to Look at How Two Different Doses of CagriSema and One Dose of Semaglutide Help People Living With Obesity With or Without Type 2 Diabetes Lose Weight." This trial seeks to enroll 2,500 participants to assess the safety and effectiveness of CagriSema for body weight loss in people with obesity, with or without type 2 diabetes.
• Pfizer is leading NCT07573462, a Phase 3 study named "A Study to Learn About the Safety of an Expanded Pneumococcal Vaccine in Healthy Infants." This trial will involve 2,400 participants and aims to learn about the safety of a new pneumococcal vaccine and how it helps fight against germs that can cause pneumonia, meningitis, and otitis media in infants, compared to existing vaccines. This study includes children as participants.
• Novo Nordisk A/S is also sponsoring two related Phase 3 studies focused on obstructive sleep apnoea: NCT07571005, "AMAZE 3: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Not Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea," and NCT07571109, "AMAZE 4: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight and Obstructive Sleep Apnoea Treated With Positive Airway Pressure Lose Weight and Improve Sleep Apnoea." Each of these studies aims to enroll 300 participants to evaluate the efficacy and safety of NNC0487-0111.
• Emory University is sponsoring NCT07563517, "Linking Individuals Needing Care for Substance Use Disorders to Peer Coaches & Across INcarceration Settings." This study aims to enroll 550 participants to learn whether a virtual peer recovery coach intervention can improve engagement in addiction treatment among incarcerated adults with substance use disorders.

Georgia's Evolving Research Landscape

This month, Georgia saw the opening of 14 new clinical trials, a decrease compared to the 28 trials that launched in March 2026. Despite this dip in new openings, the state continues to offer a broad array of research opportunities, with a total of 1,975 clinical trials currently recruiting across 100 cities and 1,313 research sites.

The majority of new research initiatives this month are concentrated in the Atlanta metropolitan area, with 11 of the 14 new trials opening in Atlanta. However, other cities across the state also saw new trial launches, indicating a continued effort to make research accessible beyond the largest urban centers. Cities with new trials include:

• Atlanta
• Lawrenceville
• Gainesville
• Conyers
• Peachtree
• Roswell
• Thomasville
• Tucker
• Union City
• Acworth

New studies are exploring a range of conditions, from common ailments to more specialized areas. This month's new trials are targeting:

• Obesity
• Obstructive sleep apnoea
• Overweight
• Heart failure
• HIV
• Lower extremity injury
• Pneumococcal disease
• Prostate cancer
• Psychological trauma
• Sickle cell disease

The types of interventions being studied are varied, with drug trials leading the way, accounting for 6 of the new trials. Other new studies include device trials (4), biological treatments (2), and behavioral interventions (1).

Diverse Participation: Healthy Volunteers and Specific Demographics

Participation in clinical trials is open to a wide range of individuals. Of the 14 new trials launched this month, 10 include older adults, ensuring that senior populations have ample opportunity to contribute to medical science. Additionally, 4 new trials are open to children, offering opportunities for younger participants to engage in research that could benefit their age group. One new trial is specifically seeking male participants.

For individuals without a specific medical condition, there are significant opportunities to contribute. 4 of the new trials this month are actively seeking healthy volunteers. Across Georgia, a total of 179 clinical trials are currently recruiting healthy participants, providing numerous avenues for those interested in supporting medical research.

Industry sponsors continue to drive a significant portion of Georgia's research efforts, accounting for 8 of the new studies this month. Academic institutions, including Emory University (3 new trials) and the University of Colorado, Denver, also play a vital role. The National Institute of Allergy and Infectious Diseases (NIAID) and Pfizer are also notable sponsors contributing to the state's research landscape.

As we move through May, the focus will likely remain on the ongoing enrollment in these significant Phase 3 trials, while researchers prepare for the next wave of innovative studies to address a broad spectrum of health challenges across Georgia.